209 related articles for article (PubMed ID: 32268953)
1. Harnessing natural killer cells for the treatment of ovarian cancer.
Hoogstad-van Evert JS; Bekkers R; Ottevanger N; Jansen JH; Massuger L; Dolstra H
Gynecol Oncol; 2020 Jun; 157(3):810-816. PubMed ID: 32268953
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer treatment and natural killer cell-based immunotherapy.
Fan Z; Han D; Fan X; Zhao L
Front Immunol; 2023; 14():1308143. PubMed ID: 38187402
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
5. Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer.
Hermanson DL; Bendzick L; Kaufman DS
Methods Mol Biol; 2016; 1441():277-84. PubMed ID: 27177674
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study).
Hoogstad-van Evert J; Bekkers R; Ottevanger N; Schaap N; Hobo W; Jansen JH; Massuger L; Dolstra H
Medicine (Baltimore); 2019 Feb; 98(5):e14290. PubMed ID: 30702598
[TBL] [Abstract][Full Text] [Related]
7. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
Front Immunol; 2019; 10():1782. PubMed ID: 31456796
[TBL] [Abstract][Full Text] [Related]
8. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
9. CD34
Van der Meer JMR; de Jonge PKJD; van der Waart AB; Geerlings AC; Moonen JP; Brummelman J; de Klein J; Vermeulen MC; Maas RJA; Schaap NPM; Hoogstad-van Evert JS; Ottevanger PB; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2021; 10(1):1981049. PubMed ID: 34616589
[TBL] [Abstract][Full Text] [Related]
10. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
Kimpo MS; Oh B; Lee S
Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
13. Harnessing NK Cells for Cancer Treatment.
Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
Front Immunol; 2019; 10():2836. PubMed ID: 31867006
[TBL] [Abstract][Full Text] [Related]
14. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
[TBL] [Abstract][Full Text] [Related]
15. Expanded CD56
Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
[TBL] [Abstract][Full Text] [Related]
16. Challenges of NK cell-based immunotherapy in the new era.
Fang F; Xiao W; Tian Z
Front Med; 2018 Aug; 12(4):440-450. PubMed ID: 30047028
[TBL] [Abstract][Full Text] [Related]
17. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the therapeutic efficacy of NK cells in the treatment of ovarian cancer (Review).
Hou Y; Zhao X; Nie X
Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38299257
[TBL] [Abstract][Full Text] [Related]
19. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
Tonn T; Becker S; Esser R; Schwabe D; Seifried E
J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
[TBL] [Abstract][Full Text] [Related]
20. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
